Sign in
Taking people in United StatesPhase 2

Valganciclovir for breast cancer that has spread to the brain with CMV infection

Tests valganciclovir in breast cancer patients with growing brain metastases and CMV.

Key facts

Who runs it
The Methodist Hospital Research Institute
Where
Houston, United StatesSee the site
Trial code
Registry title
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
Status
Recruiting
Phase
Phase 2
People taking part
28 people, planned
Started
14 Jul 2026
Expected to end
May 2030
Type of study
Interventional
Treatments tested
  • Valganciclovir
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic breast cancer whose brain metastases are growing and who also have signs of CMV (cytomegalovirus) infection. They will take oral Valganciclovir along with standard care.

Age
Over 18 years (record lists 18 Years as minimum)
Sex
Men and women can join.
Disease stage
Breast cancer that has spread, with growing brain metastases above and/or below the tentorium. At least one growing brain spot must be untreated and not radiated. Cancer elsewhere in the body may be absent, shrinking, stable or growing. ECOG performance score 0-2 (able to care for yourself at least).
Earlier treatment
At least one growing brain metastasis must not have had radiation or other treatment. SRS (focused radiation) is allowed if at least 1 lesion of 2 cm (0.8 in) or less is left untreated. No investigational product within 28 days before the first dose. No major surgery within 28 days before the first dose.
Biomarker or test result
Blood HCMV DNA by real time PCR > 250 copies/ml, or a positive CMV IgG or IgM test.

Main reasons for not taking part

  • A single brain lesion that can be removed by surgery, or all growing brain metastases already radiated.
  • Brain metastases needing urgent local treatment, such as swelling pressure or active nerve symptoms.
  • Pregnancy or breastfeeding.
  • Last brain progression-free time longer than 12 months.
  • Not speaking English, because the memory and thinking tests are only in English.

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Male or female aged >18 years at the time of consent
  • Breast cancer with progressive brain metastases supra and/or infratentorial. Patients can proceed with SRS as long as at least 1 lesion which is 2 cm or less in a noncritical area in the brain is spared as per the discretion of treating neurosurgeon/radiation oncologist
  • At least one non irradiated, untreated progressive brain metastases site
  • Serum HCMV DNA by real time PCR > 250 copies/ml or positive CMV Ig G or Ig M
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. If the patient is unable to consent for any reason a legally authorized guardian may provide consent on their behalf. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) will be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
  • Metastatic breast cancer who has systemically no evidence of disease, complete remission, partial remission, stable or progressive disease
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
  • Adequate hematology without ongoing transfusion support (hemoglobin > 9 g/dl, absolute neutrophil count (ANC) > 1500 per mm3 , platelets > 100,000 per mm3)
  • Adequate renal and hepatic function (creatinine clearance [CrCL] > 60 mL/min, bilirubin x:≤1.5 upper limit of normal (ULN), aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x ULN and serum albumin ≥ 3 g/dl
  • Other CMV treatment if clinically indicated per physician's choice
  • Evidence of postmenopausal status or negative serum pregnancy test for premenopausal female patients. Negative serum β-human chorionic gonadotropin pregnancy test within 7 days prior to the first dose of study treatment for premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause; The following age-specific requirements apply:
  • Women <50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
  • Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy)
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up

Who cannot take part

  • Brain metastases needing immediate local intervention such as mass effect, herniation, active neurological symptoms, increased intracranial pressure, those near vital structures like the motor cortex, proximity to the optic nerve/chiasm or brain stem etc (can still be included if there are any other non-radiated progressive brain metastases) Multidisciplinary discussion with neurosurgery and radiation oncology will be needed to determine which patients may be safely enrolled on the trial
  • Participation in another clinical study with an investigational product within 28 days prior to the first dose of study treatment
  • Concurrent enrollment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  • Unresolved or unstable adverse events (AEs) from prior administration of another investigational drug, per investigators' discretion
  • Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of study treatment
  • Known psychiatric disorder that causes poor cooperation with the trial requirements
  • Participants with previous other malignancies must have had at least a 3-year disease free interval, except those with non-melanoma skin cancer or carcinoma in situ of cervix
  • Single resectable intracranial lesion
  • Last intracranial progression free survival > 12 months
  • All progressive brain metastases have been radiated
  • Active pregnancy or breast feeding
  • Women of childbearing potential or fertile men unwilling to use effective contraception (Section 6.2, Table 6) during study and up to three months after treatment discontinuation
  • Non-English-speaking subjects will not be enrolled in this study since the neurocognitive tests including DKEFS, RAVLT and TMT are not validated to be scored in other languages

Where in United States

  • Houston Methodist Neal Cancer CenterHouston, United StatesContact: Akshjot Puri, M.D.Taking people

About the trial

What the trial wants to find out

This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (CMV) therapy and standard-of-care (SOC) in patients with anti-human cytomegalovirus (HCMV)-reactivated brain metastases. Male and female patients, aged ≥18 years, who have metastatic breast cancer with progressive brain metastases and CMV viremia (> 250 copies/ml) or positive CMV IgG or IgM will be eligible to participate in the trial.

Read full original descriptionShow less

Patients can proceed with SRS as long as at least 1 lesion which is 2 cm or less in a noncritical area in the brain is spared as per the discretion of treating neurosurgeon/radiation oncologist. At least 10 patients will be enrolled in the initial safety lead-in followed by the Phase II trial which will include 18 patients.

Anti-HCMV therapy, oral Valganciclovir will be given to patients at 900 mg twice a day for 2 weeks. After the induction period, the maintenance will be continued with valganciclovir at 450 mg twice daily for 4 weeks (28 days).

The group in the trial

  • Anti-HCMV therapy (Oral Valganciclovir) and Standard-of-CareTreatment being tested

    At least 10 patients will be enrolled in the initial safety lead-in followed by the Phase II trial which will include 18 patients. Anti-HCMV therapy, oral Valganciclovir will be given to patients at 900 mg twice a day for 2 weeks. After the induction period, the maintenance will be continued with valganciclovir at 450 mg twice daily for 4 weeks (28 days). CMV PCR, IgG and IgM will be checked at the end of these four weeks. Patients will be followed with physical examinations and assessment of laboratory parameters as required per standard-of-care treatment. Quality-of-life, neurocognitive questionnaires, and MRI brain (if asymptomatic) every 2 months until subsequent intracranial progression or end of study, whichever comes first. Patients will be in follow-up for 24 months.

    Treatment: Valganciclovir

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)
Plain-language title
Valganciclovir for breast cancer that has spread to the brain with CMV infectionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 August 2026